Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 517 entries
View as:

A Food Effect Study of SHR1459 on Healthy Chinese Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04291846 Org: User:
Start: 05/24/20 End: 06/29/20 Due: 06/29/21

SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03774979 Org: User:
Start: 01/24/19 End: 12/31/23 Due: 12/31/24

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03777124 Org: User:
Start: 02/28/19 End: 04/30/22 Due: 04/30/23

The Effect of SHR20004（Noiiglutide ） on Body Weight in Obese Subjects Without Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT04799327 Org: User:
Start: 03/29/21 End: 05/15/22 Due: 05/15/23

A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT04229615 Org: User:
Start: 06/02/20 End: 04/01/24 Due: 04/01/25

Bioequivalence Study of Famitinib Malate in Healthy Volunteers Under Fasting Condition

Phase: N/A Priority: Normal
NCT ID: NCT05336279 Org: User:
Start: 05/11/22 End: 06/20/22 Due: 06/20/23

A Phase 1, Randomized, Placebo-controlled, Multiple Dose Escalation Study to Investigate Safety, Pharmacokinetics, and Pharmacodynamics of SHR0534 in Chinese Type 2 Diabetic Patients

Phase: N/A Priority: Normal
NCT ID: NCT03006159 Org: User:
Start: 03/31/15 End: 03/31/16 Due: 03/31/17

Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03707509 Org: User:
Start: 11/13/18 End: 12/31/22 Due: 12/31/23

Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage

Phase: N/A Priority: Normal
NCT ID: NCT04849000 Org: User:
Start: 04/23/21 End: 01/13/23 Due: 01/13/24

A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Oral HRS-5041 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT07014488 Org: User:
Start: 06/30/25 End: 07/31/25 Due: 07/31/26

Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05252546 Org: User:
Start: 03/08/22 End: 08/02/22 Due: 08/02/23

Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia

Phase: N/A Priority: Normal
NCT ID: NCT03185793 Org: User:
Start: 07/20/17 End: 07/20/18 Due: 07/20/19

The Multiple Dose of PK/PD Study of SHR2285 Tablets in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04229433 Org: User:
Start: 08/11/20 End: 11/08/20 Due: 11/08/21

A Trial of Hetrombopag in Healthy and Hepatic Impairment Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05088642 Org: User:
Start: 09/28/20 End: 12/04/20 Due: 12/04/21

A Pharmacokinetic Study to Evaluate the Drug Interaction Between HRS5091 and Probe Drugs in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT05273775 Org: User:
Start: 04/29/22 End: 06/23/22 Due: 06/23/23

A SHR0302 BA Study on Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT06202612 Org: User:
Start: 01/16/24 End: 02/21/24 Due: 02/21/25

A Study of SHR-9803 for Injection in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06906731 Org: User:
Start: 04/30/25 End: 12/31/27 Due: 12/31/28

Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04383977 Org: User:
Start: 05/31/20 End: 06/30/21 Due: 06/30/22

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Phase: N/A Priority: Normal
NCT ID: NCT05367687 Org: User:
Start: 09/01/22 End: 04/30/26 Due: 04/30/27

A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis.

Phase: N/A Priority: Normal
NCT ID: NCT05476900 Org: User:
Start: 10/06/22 End: 03/14/25 Due: 03/14/26

Phase I Study of HRS-7053 Injection in the Treatment of Patients With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT05983146 Org: User:
Start: 09/01/23 End: 06/30/27 Due: 06/30/28

Apatinib Dose Titration in Advanced or Metastatic Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02764268 Org: User:
Start: 11/02/16 End: 04/15/19 Due: 04/15/20

A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03871855 Org: User:
Start: 04/28/19 End: 06/21/21 Due: 06/21/22

A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06308406 Org: User:
Start: 03/15/24 End: 10/31/25 Due: 10/31/26

Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Liver Function

Phase: N/A Priority: Normal
NCT ID: NCT04694365 Org: User:
Start: 03/01/21 End: 06/19/24 Due: 06/19/25